Clinical and laboratory characteristics of patients hospitalised with COVID-19: clinical outcomes in Abu Dhabi, United Arab Emirates
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was first reported in December 2019. The severity of coronavirus disease 2019 (COVID-19) ranges from asymptomatic to severe and potentially fatal. We aimed to describe the clinical and laboratory features and outcomes of hospitalised patients with COVID-19 within the Abu Dhabi Healthcare Services Facilities (SEHA). Methods Our retrospective analysis of patient data collected from electronic health records (EHRs) available from the SEHA health information system included all patients admitted from 1 March to 31 May 2020 with a laboratory-confirmed PCR diagnosis of SARS-CoV-2 infection. Data of clinical features, co-morbidities, laboratory markers, length of hospital stay, treatment received and mortality were analysed according to severe versus non-severe disease. Results The study included 9390 patients. Patients were divided into severe and non-severe groups. Seven hundred twenty-one (7.68%) patients required intensive care, whereas the remaining patients (92.32%) had mild or moderate disease. The mean patient age of our cohort (41.8 years) was lower than the global average. Our population had male predominance, and it included various nationalities. The major co-morbidities were hypertension, diabetes mellitus and chronic kidney disease. Laboratory tests revealed significant differences in lactate dehydrogenase, ferritin, C-reactive protein, interleukin-6 and creatinine levels and the neutrophil count between the severe and non-severe groups. The most common anti-viral therapy was the combination of Hydroxychloroquine and Favipiravir. The overall in-hospital mortality rate was 1.63%, although the rate was 19.56% in the severe group. The mortality rate was higher in adults younger than 30 years than in those older than 60 years (2.3% vs. 0.95%). Conclusions Our analysis suggested that Abu Dhabi had lower COVID-19 morbidity and mortalities rates were less than the reported rates then in China, Italy and the US. The affected population was relatively young, and it had an international representation. Globally, Abu Dhabi had one of the highest testing rates in relation to the population volume. We believe the early identification of patients and their younger age resulted in more favourable outcomes..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
BMC Infectious Diseases - 22(2022), 1, Seite 9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mariam Al Harbi [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.1186/s12879-022-07059-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ074659189 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ074659189 | ||
| 003 | DE-627 | ||
| 005 | 20230502123932.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12879-022-07059-1 |2 doi | |
| 035 | |a (DE-627)DOAJ074659189 | ||
| 035 | |a (DE-599)DOAJ4eac167bd46049bc99c8f5fe115638ad | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Mariam Al Harbi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and laboratory characteristics of patients hospitalised with COVID-19: clinical outcomes in Abu Dhabi, United Arab Emirates |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was first reported in December 2019. The severity of coronavirus disease 2019 (COVID-19) ranges from asymptomatic to severe and potentially fatal. We aimed to describe the clinical and laboratory features and outcomes of hospitalised patients with COVID-19 within the Abu Dhabi Healthcare Services Facilities (SEHA). Methods Our retrospective analysis of patient data collected from electronic health records (EHRs) available from the SEHA health information system included all patients admitted from 1 March to 31 May 2020 with a laboratory-confirmed PCR diagnosis of SARS-CoV-2 infection. Data of clinical features, co-morbidities, laboratory markers, length of hospital stay, treatment received and mortality were analysed according to severe versus non-severe disease. Results The study included 9390 patients. Patients were divided into severe and non-severe groups. Seven hundred twenty-one (7.68%) patients required intensive care, whereas the remaining patients (92.32%) had mild or moderate disease. The mean patient age of our cohort (41.8 years) was lower than the global average. Our population had male predominance, and it included various nationalities. The major co-morbidities were hypertension, diabetes mellitus and chronic kidney disease. Laboratory tests revealed significant differences in lactate dehydrogenase, ferritin, C-reactive protein, interleukin-6 and creatinine levels and the neutrophil count between the severe and non-severe groups. The most common anti-viral therapy was the combination of Hydroxychloroquine and Favipiravir. The overall in-hospital mortality rate was 1.63%, although the rate was 19.56% in the severe group. The mortality rate was higher in adults younger than 30 years than in those older than 60 years (2.3% vs. 0.95%). Conclusions Our analysis suggested that Abu Dhabi had lower COVID-19 morbidity and mortalities rates were less than the reported rates then in China, Italy and the US. The affected population was relatively young, and it had an international representation. Globally, Abu Dhabi had one of the highest testing rates in relation to the population volume. We believe the early identification of patients and their younger age resulted in more favourable outcomes. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical features | |
| 650 | 4 | |a Disease severity | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Outcome | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Nawal Al Kaabi |e verfasserin |4 aut | |
| 700 | 0 | |a Asma Al Nuaimi |e verfasserin |4 aut | |
| 700 | 0 | |a Jehad Abdalla |e verfasserin |4 aut | |
| 700 | 0 | |a Tehmina Khan |e verfasserin |4 aut | |
| 700 | 0 | |a Huda Gasmelseed |e verfasserin |4 aut | |
| 700 | 0 | |a Asad Khan |e verfasserin |4 aut | |
| 700 | 0 | |a Osama Hamdoun |e verfasserin |4 aut | |
| 700 | 0 | |a Stefan Weber |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t BMC Infectious Diseases |d BMC, 2003 |g 22(2022), 1, Seite 9 |w (DE-627)DOAJ000056693 |x 14712334 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:1 |g pages:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12879-022-07059-1 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/4eac167bd46049bc99c8f5fe115638ad |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12879-022-07059-1 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1471-2334 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 1 |h 9 | ||